Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados Biol. Res. (2) Autor KATO,SUMIE (2) OWEN,GARETH I (2) ARANDA,EVELYN (1) CARVAJAL,ANDRÉS (1) MEDINA,RODOLFO A (1) MONSO,CAROLINA (1) PINTO,MAURICIO (1) SADARANGANI,ANIL (1) SALGADO,ANA MARÍA (1) VERDUGO,CESAR (1) VIGIL,PILAR (1) Mais... Palavra-chave Atherosclerosis cardiovascular disease (1) Breast/endometrium cancer estrogenic HRT progestagenic &amp (1) Estrogen (1) Hormone replacement therapy (HRT) (1) Myocardial infarction (1) Oral contraceptives (1) Progestins (1) Tibolone (1) Venous thrombosis (1) Mais... Tipo do documento Journal article (2) Ano 2005 (1) 2003 (1) País Chile (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última The action of ovarian hormones in cardiovascular disease Biol. Res. MEDINA,RODOLFO A; ARANDA,EVELYN; VERDUGO,CESAR; KATO,SUMIE; OWEN,GARETH I. The incidence of cardiovascular disease (CAD) differs between men and women, in part because of differences in risk factors and hormones. This sexual dimorphism means a lower incidence in atherosclerotic diseases in premenopausal women, which subsequently rises in postmenopausal women to eventually equal that of men. These observations point towards estrogen and progesterone playing a lifetime protective role against CAD in women. As exogenous estrogen and estrogen plus progesterone preparations produce significant reductions in low-density lipoprotein (LDL) cholesterol levels and significant increases in high-density lipoprotein (HDL) cholesterol, this should in theory lower the risk of CAD. However, results from oral contraceptive (OC) use and combined... Tipo: Journal article Palavras-chave: Hormone replacement therapy (HRT); Oral contraceptives; Atherosclerosis cardiovascular disease; Estrogen; Progestins; Venous thrombosis; Myocardial infarction. Ano: 2003 URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602003000300005 In vivo and in vitro estrogenic and progestagenic actions of Tibolone Biol. Res. SADARANGANI,ANIL; SALGADO,ANA MARÍA; KATO,SUMIE; PINTO,MAURICIO; CARVAJAL,ANDRÉS; MONSO,CAROLINA; OWEN,GARETH I; VIGIL,PILAR. Estrogen and progestin combination in hormone replacement therapy (HRT) increases the incidence of breast cancer, but decreases the endometrial cancer risk of unopposed estrogen. Therefore, a SERM such as Tibolone, that delivers the beneficial, but not the adverse side effects, of steroid hormones would be clinically advantageous. However, data from the Million Women Study suggests that Tibolone increases the risk of both breast and endometrial cancer. Herein, we assessed the estrogenic and progestagenic actions of Tibolone using transvaginal sonography studies and an in vitro model of breast (ZR-75, MCF7) and endometrial cancer (Ishikawa). The known cancer associated proteins (ER, EGFR, STAT5, tissue factor and Bcl-xL) were selected for study.... Tipo: Journal article Palavras-chave: Breast/endometrium cancer estrogenic HRT progestagenic & Tibolone. Ano: 2005 URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602005000200014 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco